Literature DB >> 18926869

Antibodies and cytokines independently protect against pneumonic plague.

Lawrence W Kummer1, Frank M Szaba, Michelle A Parent, Jeffrey J Adamovicz, Jim Hill, Lawrence L Johnson, Stephen T Smiley.   

Abstract

Yersinia pestis causes pneumonic plague, an exceptionally virulent disease for which we lack a safe and effective vaccine. Antibodies specific for the Y. pestis F1 and LcrV proteins can protect mice against pulmonary Y. pestis infection. We demonstrate that neutralizing tumor necrosis factor-alpha (TNFalpha) and gamma-interferon (IFNgamma) abrogates this protection at sub-optimal levels of F1- or LcrV-specific antibody, but not at optimal levels. Moreover, we demonstrate that endogenous TNFalpha and IFNgamma confer measurable protection in the complete absence of protective antibodies. These findings indicate that antibodies and cytokines independently protect against pneumonic plague and suggest that surrogate assays for plague vaccine efficacy should consider both the level of vaccine-induced antibody and the capacity of vaccine recipients to produce TNFalpha and IFNgamma upon exposure to Y. pestis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926869      PMCID: PMC2631396          DOI: 10.1016/j.vaccine.2008.09.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  37 in total

1.  A plasminogen-activating protease specifically controls the development of primary pneumonic plague.

Authors:  Wyndham W Lathem; Paul A Price; Virginia L Miller; William E Goldman
Journal:  Science       Date:  2007-01-26       Impact factor: 47.728

2.  Plague bacillus: survival within host phagocytes.

Authors:  W A Janssen; M J Surgalla
Journal:  Science       Date:  1969-02-28       Impact factor: 47.728

Review 3.  Risk of person-to-person transmission of pneumonic plague.

Authors:  Jacob L Kool
Journal:  Clin Infect Dis       Date:  2005-03-16       Impact factor: 9.079

4.  Development of in vitro correlate assays of immunity to infection with Yersinia pestis.

Authors:  J Bashaw; S Norris; S Weeks; S Trevino; J J Adamovicz; S Welkos
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

5.  Human immune response to a plague vaccine comprising recombinant F1 and V antigens.

Authors:  E D Williamson; H C Flick-Smith; C Lebutt; C A Rowland; S M Jones; E L Waters; R J Gwyther; J Miller; P J Packer; M Irving
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

6.  Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops).

Authors:  K J Davis; D L Fritz; M L Pitt; S L Welkos; P L Worsham; A M Friedlander
Journal:  Arch Pathol Lab Med       Date:  1996-02       Impact factor: 5.534

7.  A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene.

Authors:  D Kitamura; J Roes; R Kühn; K Rajewsky
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

8.  The ability to replicate in macrophages is conserved between Yersinia pestis and Yersinia pseudotuberculosis.

Authors:  Céline Pujol; James B Bliska
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

9.  Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.

Authors:  R Nakajima; R R Brubaker
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

Review 10.  Current challenges in the development of vaccines for pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Expert Rev Vaccines       Date:  2008-03       Impact factor: 5.217

View more
  29 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Deletion of Braun lipoprotein and plasminogen-activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague.

Authors:  Christina J van Lier; Jian Sha; Michelle L Kirtley; Anthony Cao; Bethany L Tiner; Tatiana E Erova; Yingzi Cong; Elena V Kozlova; Vsevolod L Popov; Wallace B Baze; Ashok K Chopra
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.

Authors:  Fahreta Hamzabegovic; Johannes B Goll; William F Hooper; Sharon Frey; Casey E Gelber; Getahun Abate
Journal:  NPJ Vaccines       Date:  2020-01-23       Impact factor: 7.344

4.  IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection.

Authors:  Jr-Shiuan Lin; Lawrence W Kummer; Frank M Szaba; Stephen T Smiley
Journal:  J Immunol       Date:  2010-12-20       Impact factor: 5.422

5.  Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.

Authors:  Wei Sun; Kenneth L Roland; Xiaoying Kuang; Christine G Branger; Roy Curtiss
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

6.  Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis.

Authors:  Deyan Luo; Jr-Shiuan Lin; Michelle A Parent; Isis Mullarky-Kanevsky; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Michael Tighe; Jim Hill; Andras Gruber; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2013-03-13       Impact factor: 5.422

7.  D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.

Authors:  Frank M Szaba; Lawrence W Kummer; Lindsey B Wilhelm; Jr-Shiuan Lin; Michelle A Parent; Sara W Montminy-Paquette; Egil Lien; Lawrence L Johnson; Stephen T Smiley
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

8.  Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages.

Authors:  Betty L Noel; Sarit Lilo; Daniel Capurso; Jim Hill; James B Bliska
Journal:  Clin Vaccine Immunol       Date:  2009-08-26

9.  Absence of inflammation and pneumonia during infection with nonpigmented Yersinia pestis reveals a new role for the pgm locus in pathogenesis.

Authors:  Hanni Lee-Lewis; Deborah M Anderson
Journal:  Infect Immun       Date:  2009-10-19       Impact factor: 3.441

10.  The role of relA and spoT in Yersinia pestis KIM5 pathogenicity.

Authors:  Wei Sun; Kenneth L Roland; Christine G Branger; Xiaoying Kuang; Roy Curtiss
Journal:  PLoS One       Date:  2009-08-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.